Investors Sell Shares of Gilead Sciences (GILD) on Strength (GILD)

Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading hours on Thursday. $63.70 million flowed into the stock on the tick-up and $110.13 million flowed out of the stock on the tick-down, for a money net flow of $46.43 million out of the stock. Of all stocks tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.05 for the day and closed at $71.52

A number of brokerages have recently commented on GILD. BidaskClub downgraded shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Piper Jaffray Companies began coverage on shares of Gilead Sciences in a research report on Wednesday, May 30th. They issued a “buy” rating and a $85.00 price objective for the company. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. Finally, Morgan Stanley decreased their price objective on shares of Gilead Sciences from $85.00 to $81.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $88.00.

The company has a current ratio of 2.84, a quick ratio of 2.75 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $92.99 billion, a price-to-earnings ratio of 8.30, a PEG ratio of -6.22 and a beta of 1.15.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the consensus estimate of $1.67 by ($0.19). Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The business had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.40 billion. During the same quarter last year, the firm earned $2.23 EPS. Gilead Sciences’s revenue for the quarter was down 21.8% compared to the same quarter last year. equities research analysts expect that Gilead Sciences, Inc. will post 5.75 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 3.21%. The ex-dividend date is Thursday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $72.19, for a total value of $3,609,500.00. Following the completion of the sale, the director now owns 3,067,762 shares in the company, valued at approximately $221,461,738.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction that occurred on Friday, April 6th. The shares were sold at an average price of $74.47, for a total transaction of $434,383.51. Following the completion of the transaction, the director now owns 58,452 shares of the company’s stock, valued at $4,352,920.44. The disclosure for this sale can be found here. Insiders sold a total of 179,168 shares of company stock valued at $12,789,233 in the last quarter. Corporate insiders own 1.30% of the company’s stock.

Large investors have recently modified their holdings of the company. Parnassus Investments CA raised its position in shares of Gilead Sciences by 2.5% in the 4th quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock valued at $1,372,604,000 after buying an additional 464,609 shares in the last quarter. Hyman Charles D raised its position in shares of Gilead Sciences by 35.9% in the 4th quarter. Hyman Charles D now owns 4,164 shares of the biopharmaceutical company’s stock valued at $298,000 after buying an additional 1,100 shares in the last quarter. James Investment Research Inc. raised its position in shares of Gilead Sciences by 23.2% in the 4th quarter. James Investment Research Inc. now owns 40,524 shares of the biopharmaceutical company’s stock valued at $2,903,000 after buying an additional 7,644 shares in the last quarter. Accident Compensation Corp raised its position in shares of Gilead Sciences by 3.2% in the 4th quarter. Accident Compensation Corp now owns 64,097 shares of the biopharmaceutical company’s stock valued at $4,592,000 after buying an additional 2,000 shares in the last quarter. Finally, Financial Advisors Network Inc. raised its position in shares of Gilead Sciences by 1,964.0% in the 4th quarter. Financial Advisors Network Inc. now owns 127,330 shares of the biopharmaceutical company’s stock valued at $9,122,000 after buying an additional 121,161 shares in the last quarter. Institutional investors own 77.60% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply